Molecular imaging of biological gene delivery vehicles for targeted cancer therapy: Beyond viral vectors

被引:9
|
作者
Min J.-J. [1 ]
Nguyen V.H. [1 ]
Gambhir S.S. [2 ]
机构
[1] Department of Nuclear Medicine, Chonnam National University Medical School, Dong-gu, Gwangju 501-746
[2] Molecular Imaging Program, Department of Radiology and Bioengineering, Bio-X Program, Stanford University, Stanford
基金
新加坡国家研究基金会;
关键词
Cancer; Gene delivery vector; Gene therapy; Molecular imaging;
D O I
10.1007/s13139-009-0006-3
中图分类号
学科分类号
摘要
Cancer persists as one of the most devastating diseases in the world. Problems including metastasis and tumor resistance to chemotherapy and radiotherapy have seriously limited the therapeutic effects of present clinical treatments. To overcome these limitations, cancer gene therapy has been developed over the last two decades for a broad spectrum of applications, from gene replacement and knockdown to vaccination, each with different requirements for gene delivery. So far, a number of genes and delivery vectors have been investigated, and significant progress has been made with several gene therapy modalities in clinical trials. Viral vectors and synthetic liposomes have emerged as the vehicles of choice for many applications. However, both have limitations and risks that restrict gene therapy applications, including the complexity of production, limited packaging capacity, and unfavorable immunological features. While continuing to improve these vectors, it is important to investigate other options, particularly nonviral biological agents such as bacteria, bacteriophages, and bacteria-like particles. Recently, many molecular imaging techniques for safe, repeated, and high-resolution in vivo imaging of gene expression have been employed to assess vector-mediated gene expression in living subjects. In this review, molecular imaging techniques for monitoring biological gene delivery vehicles are described, and the specific use of these methods at different steps is illustrated. Linking molecular imaging to gene therapy will eventually help to develop novel gene delivery vehicles for preclinical study and support the development of future human applications. © Korean Society of Nuclear Medicine 2010.
引用
收藏
页码:15 / 24
页数:9
相关论文
共 50 条
  • [41] Viral vectors for gene therapy
    Robbins, PD
    Ghivizzani, SC
    PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) : 35 - 47
  • [42] Application of Non-Viral Vectors in Drug Delivery and Gene Therapy
    Ren, Shuaikai
    Wang, Mengjie
    Wang, Chunxin
    Wang, Yan
    Sun, Changjiao
    Zeng, Zhanghua
    Cui, Haixin
    Zhao, Xiang
    POLYMERS, 2021, 13 (19)
  • [43] Renal targeted gene delivery vectors
    Denby, Laura
    Work, Lorraine M.
    Von Seggern, Dan J.
    Wu, Eugene
    Hunt, Ela
    Nicklin, Stuart A.
    Baker, Andrew H.
    JOURNAL OF HYPERTENSION, 2006, 24 : 179 - 179
  • [44] Targeted synthetic gene delivery vectors
    Schaffer, DV
    Lauffenburger, DA
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2000, 2 (02) : 155 - 161
  • [45] Non-viral vectors for gene therapy and drug delivery - Preface
    Safinya, CR
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (02)
  • [46] Viral vectors and delivery systems for gene therapy in cardiovascular medicine - The intersection of molecular biology and interventional cardiology
    Flugelman, MY
    Halon, DA
    Lewis, BS
    CORONARY ARTERY DISEASE: PREVENTION TO INTERVENTION, 2000, : 13 - 17
  • [47] Advances in delivery vectors for gene therapy in liver cancer
    Bowman, Katherine E. Redd
    Phong Lu
    Vander Mause, Erica R.
    Lim, Carol S.
    THERAPEUTIC DELIVERY, 2020, 11 (01) : 833 - 850
  • [48] Gene Therapy for Cancer: Dairy Bacteria as Delivery Vectors
    Tangney, Mark
    DISCOVERY MEDICINE, 2010, 10 (52) : 195 - 200
  • [49] Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
    Kay, MA
    Glorioso, JC
    Naldini, L
    NATURE MEDICINE, 2001, 7 (01) : 33 - 40
  • [50] Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
    Mark A. Kay
    Joseph C Glorioso
    Luigi Naldini
    Nature Medicine, 2001, 7 : 33 - 40